Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer.
Erb HHH, Bodenbender J, Handle F, Diehl T, Donix L, Tsaur I, Gleave M, Haferkamp A, Huber J, Fuessel S, Juengel E, Culig Z, Thomas C.
Erb HHH, et al.
PLoS One. 2020 Aug 13;15(8):e0237248. doi: 10.1371/journal.pone.0237248. eCollection 2020.
PLoS One. 2020.
PMID: 32790723
Free PMC article.